Trial Profile
A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Feb 2022 Status changed from active, no longer recruiting to completed.
- 17 Jun 2021 Results of a cost-effectiveness secondary analysis using data from this trial presented at the 26th Congress of the European Haematology Association
- 01 May 2021 Results published in the American Journal of Hematology